Table 3.

Best overall response by independent central review per RECIST v1.1.

Pembrolizumab 200 mg Q3WPembrolizumab 200 mg Q3W
+ ipilimumab 50 mg Q6W+ ipilimumab 100 mg Q12W
(n = 51)(n = 51)
Objective response rate
N2831
 % (95% CIa)55 (40–69)61 (46–74)
Best overall response, n (%)
 Complete response8 (16)13 (25)
 Partial response20 (39)18 (35)
 Stable disease10 (20)8 (16)
 Progressive disease8 (16)5 (10)
 Disease not measurable per central review at baseline, that did not completely resolve or progress2 (4)5 (10)
 Non-evaluable1 (2)1 (2)
 No assessment done2 (4)1 (2)
Time to response in months, median (range)1.4 (1.3–8.3)1.5 (1.3–10.9)
Duration of response in months, median (range)Not reached (1.4+ to 17.9+)Not reached (2.8+ to 18.3+)
  • Abbreviations: Q3W, every 3 weeks; Q6W, every 6 weeks; Q12W, every 12 weeks; RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1.

  • aBased on binomial exact confidence interval method.